One of the great unanswered questions (so far) is whether adding a tyrosine kinase inhibitor (a TKI) to docetaxel + prednisone can improve outcomes for men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, cediranib, mCRPC, metastatic, TKI, tyrosine kinase inhibitor | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
